BiotechTube

Remimazolam Tosilate

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Sedation in the Upper Gastrointestinal Endoscopy

Conditions

Sedation in the Upper Gastrointestinal Endoscopy

Trial Timeline

Dec 11, 2023 → Dec 16, 2023

NCT ID
NCT06169995

About Remimazolam Tosilate

Remimazolam Tosilate is a approved stage product being developed by Jiangsu Hengrui Medicine for Sedation in the Upper Gastrointestinal Endoscopy. The current trial status is completed. This product is registered under clinical trial identifier NCT06169995. Target conditions include Sedation in the Upper Gastrointestinal Endoscopy.

What happened to similar drugs?

7 of 20 similar drugs in Sedation in the Upper Gastrointestinal Endoscopy were approved

Approved (7) Terminated (2) Active (13)
🔄AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3
✅Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
✅fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
🔄Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
🔄Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3
🔄Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06169995ApprovedCompleted
NCT05913336Phase 1/2Completed

Competing Products

20 competing products in Sedation in the Upper Gastrointestinal Endoscopy

See all competitors
ProductCompanyStageHype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3
40
Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
35
fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
43
AQUAVAN® (fospropofol disodium) InjectionEisaiPhase 2/3
38
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
35
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Remimazolam TosilateJiangsu Hengrui MedicinePhase 1/2
32
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
26
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
40
Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3
40
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
40
SHR0302 Base Gel + SHR0302 Base Gel PlaceboJiangsu Hengrui MedicinePhase 1
29
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
26
Remimazolam Tosilate for Injection + Remimazolam Tosilate for InjectionJiangsu Hengrui MedicineApproved
39
Remimazolam Tosilate for injection + Propofol InjectionJiangsu Hengrui MedicinePhase 2/3
45
Dexmedetomidine hydrochloride nasal spray + Dexmedetomidine hydrochloride nasal spray blank preparation.Jiangsu Hengrui MedicinePhase 1
29
Intranasal Dexmedetomidine + Intravenous Dexmedetomidine + Intranasal Placebo + Intravenous PlaceboJiangsu Hengrui MedicinePhase 1
25
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 2
35
dexmedetomidine nasal spray + dexmedetomidine hydrochloride nasal spray blank preparationJiangsu Hengrui MedicinePhase 2/3
34
Remimazolam Tosilate + Propofol Injection.Jiangsu Hengrui MedicinePhase 2
35